iShares 1-5 Year Investment Grade Corporate Bond ETF
BlackRock, Inc. IGSB ETF
| IGSB Price | $52.83 |
Market Cap | $21.95B |
| Annual Dividend Yield | 4.26% |
Annual Dividend | $2.25 |
| Yearly Management Fee | 0.04% |
Asset Class | Fixed income |
| Focus | |
Category | Corporate, Broad-based |
| Niche | Short-term |
Last 24h Volume | $1.93M |
| Portfolio Management Company | BlackRock, Inc. |
Discount/Premium to NAV | 0.05% |
| Inception Date | Jan 05, 2007 |
Market Cap Rank | 102 |
| Monthly AUM Growth | 1.61% |
Holdings Region | North America |
| Management Style | Passive |
Leverage | Non-Leveraged |
| Description | Best investment Environment | Expected Return |
Invests in 1-5 year investment-grade corporate bonds. This fund includes corporate bonds with high credit ratings and provides fixed income. |
Low interest rates, improving corporate credit quality, short-to-medium term income seeking |
Low return potential, low risk. |
iShares 1-5 Year Investment Grade Corporate Bond ETF is an ETF issued by BlackRock, Inc. on Jan 05 2007.
The main focus of this ETF, which is in the "Fixed income" asset class, is determined as "".
As of today, the price of IGSB ETF according to its net asset value is premiumed at 0.05%.
While the total value of the fund shows $348.14M increase compared to the previous month, its price is traded daily at a increase of 0.06%.
The annual dividend yield of IGSB ETF is 4.26%, whereas its main asset area is North America.
IGSB ETF, whose 24-hour total volume is $1.93M, has experienced a $254.77M cash inflow in the last month.
In addition, iShares 1-5 Year Investment Grade Corporate Bond ETF's one-year net asset value total return is 5.88%.
IGSB ETF Returns
| Daily |
Weekly |
Monthly |
3 Mo |
6 Mo |
YTD |
Yearly |
| 0.06% |
0.23% |
0.46% |
1.17% |
1.58% |
2.07% |
1.48% |
IGSB ETF NAV Total Return
| Monthly |
3 Mo |
YTD |
Yearly |
3 Years |
5 Years |
| 0.81% |
2.15% |
4.74% |
5.88% |
16.07% |
11.28% |
IGSB ETF Fund Flows Chart
IGSB ETF Market Cap Chart
IGSB ETF NAV Growth Chart
IGSB ETF Comments
no comments yet